BLCO at a glance
Bausch & Lomb Corp (BLCO, SEC CIK 1860742) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as November 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bausch & Lomb Corp (BLCO) reported revenue of $5.1 billion (up 6.5% from FY2024) and a net loss of $360.0 million. Diluted EPS was -$1.02.
- As of September 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Bausch & Lomb Corp (BLCO) shares worth $180.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Munsch Frederick on October 29, 2026 of 112,015 shares at $20.48 per share.
- In the last 90 days, BLCO insiders reported 0 open-market purchases ($0) and 1 open-market sale ($2.3M) on Form 4, a net sale of $2.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.1B
- +6.5% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$2.3M
- 13F holders
- 18 funds
- $180.5M · +1 vs prior quarter
- Latest 8-K
- Oct 28, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $1,375M, up 7% YoY from $1,281M, driven by volume, pricing and acquisitions
- Cost of goods sold margin 35.4% vs 39.9% YoY, supporting operating income of $155M vs $95M
- Pharmaceuticals strongest growth: revenue $367M, up 11%; Vision Care largest segment at $774M
- Operating cash flow $418M for nine months vs $147M YoY; investing cash use $290M, including $35M MIEBO milestone payment
- Near-term headwinds: evolving tariffs, FDA Tampa warning letter, geopolitical conflicts and healthcare pricing pressure.calc
Risk Factors
- Leadership transition risk: Thomas Appio became interim CEO October 12, 2026, following Brent Saunders’ departure
- Governance conflict risk: Appio’s concurrent Bausch Health CEO role may divide management attention
- Strategic execution risk: New chairman and interim CEO may change business strategy, creating stakeholder uncertainty
- Market risk: Leadership disruption could reduce the market value of common shares
AI summary of the BLCO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.375B, up 7% reported and 8% constant currency, with growth across all three segments
- Adjusted EBITDA $325M, up $82M year over year, signaling stronger operating leverage and efficiency
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 announces Bausch + Lomb’s results for the quarter ended September 30, 2026
- Investors should review the attached release for revenue, earnings, guidance, and operating performance details
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Nathalie Bernier resigned from the Board and Science and Technology Committee effective October 28, 2026
- Board does not currently plan to fill the vacancy, reducing director headcount and committee capacity
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Brent Saunders departed October 12, 2026, also leaving the board, with no reported dispute or disagreement
- Chairman Thomas J. Appio appointed interim CEO while continuing as Bausch Health CEO, increasing parent-company influence
Item EX-99.1: Item EX-99.1
- Thomas J. Appio appointed interim CEO immediately while retaining Bausch Health CEO role
- Brent Saunders departing by mutual agreement, creating leadership transition risk for BLCO
Item 7.01: Regulation FD Disclosure
- CEO Saunders’ departure and Mr. Appio’s appointment as interim CEO, signaling an immediate leadership transition
- Expected 2026 adjusted EBITDA guidance increase, excluding Acquired IPR&D, indicating improved outlook for underlying profitability
AI summaries of BLCO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BLCO
Don't miss the next BLCO filing
- Alerts as it files. A push when BLCO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BLCO, by share count.
- Ask anything. An AI agent that reads every BLCO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Munsch Frederick | M | Oct 29, 2026 | 24,103 | $17.96 |
| Alfonso Eduardo | A | Oct 29, 2026 | 1,125 | $20.40 |
| Munsch Frederick | M | Oct 29, 2026 | 24,103 | - |
| Munsch Frederick | M | Oct 29, 2026 | 87,912 | - |
| ROBERTSON RUSSEL C | A | Oct 29, 2026 | 1,256 | $20.40 |
| Paulson John | A | Oct 29, 2026 | 1,125 | $20.40 |
| Munsch Frederick | M | Oct 29, 2026 | 87,912 | $18.00 |
| Munsch Frederick | Sell | Oct 29, 2026 | 112,015 | $20.48 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.8B | $5.1B |
| Operating Income | - | $162.0M | $113.0M |
| Net Income | -$260.0M | -$317.0M | -$360.0M |
| Op. Margin | - | 3.4% | 2.2% |
| Net Margin | - | -6.6% | -7.1% |
| Balance Sheet | |||
| Total Assets | $13.4B | $13.5B | $14.0B |
| Equity | - | $6.5B | $6.4B |
| ROE | - | -4.9% | -5.6% |
| Per Share | |||
| EPS | $-0.74 | $-0.90 | $-1.02 |
| Cash Flow | |||
| Operating CF | - | $232.0M | $283.0M |
| CapEx | $181.0M | $291.0M | $349.0M |
Source: XBRL data in Bausch & Lomb Corp (BLCO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BLCO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 18 | $180.5M |
| Q2 2026 | 17 | $196.4M |
| Q1 2026 | 18 | $166.7M |
| Q4 2025 | 16 | $194.6M |
| Q3 2025 | 15 | $169.5M |
| Q2 2025 | 17 | $131.7M |
| Q1 2025 | 15 | $118.0M |
| Q4 2024 | 13 | $146.4M |
- JPMorgan Chase & Co+178.0K (+147%)
- T. Rowe Price Group+71.7K (+3%)
- D.E. Shaw & Co+56.7K (+2%)
- Citadel Advisors LLC+20.3K (+2%)
- Two Sigma Investments+16.3K (+32%)
- Carl Icahn−1.12M (-32%)
- Goldman Sachs Group−316.7K (-75%)
- Millennium Management−126.0K (-71%)
- Morgan Stanley−43.0K (-6%)
- Bank of America Corp−18.5K (-38%)
- Mangrove Partners+20.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 129 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BLCO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 4 | Nov 2, 2026 | - | - | - |
| 10-Q | Oct 28, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | - | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
Related Health Care companies
- COO · Cooper Companies (The)Ophthalmic Goods
- EYE · National Vision Holdings, Inc.Ophthalmic Goods
- RXST · RxSight, Inc.Ophthalmic Goods
- STAA · STAAR SURGICAL COOphthalmic Goods
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
BLCO SEC filings: frequently asked questions
Are BLCO insiders buying or selling?
In the last 90 days, Bausch & Lomb Corp (BLCO) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $2.3 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BLCO stock?
As of September 30, 2026, the largest Bausch & Lomb Corp (BLCO) holders among the 13F filers tracked by SignalX were D.E. Shaw & Co ($57.5 million), Carl Icahn ($40.4 million), T. Rowe Price Group ($38.0 million), Citadel Advisors LLC ($17.1 million), Morgan Stanley ($11.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BLCO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bausch & Lomb Corp (BLCO) reported revenue of $5.1 billion (up 6.5% from FY2024) and a net loss of $360.0 million. Diluted EPS was -$1.02. The figures come from the XBRL data in the 10-K.
What did BLCO report in its latest 8-K?
Bausch & Lomb Corp (BLCO) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $1.375B, up 7% reported and 8% constant currency, with growth across all three segments.
What are the latest BLCO SEC filings?
Bausch & Lomb Corp (BLCO) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on November 2, 2026.
What is BLCO's SEC CIK number?
Bausch & Lomb Corp (BLCO)'s SEC Central Index Key (CIK) is 1860742. EDGAR lists every BLCO filing under that number.
Ask anything about BLCO
The research agent reads BLCO's filings, financials, insider trades and 13F holders, then answers with sources.